|Market Size in 2022||Market Forecast in 2030||CAGR (in %)||Base Year|
|USD 7.45 Billion||USD 18.65 Billion||12.18%||2022|
High-flow Nasal Cannula Market
The global high-flow nasal cannula market size was worth around USD 7.45 billion in 2022 and is predicted to grow to around USD 18.65 billion by 2030 with a compound annual growth rate (CAGR) of roughly 12.18% between 2023 and 2030.
A high-flow nasal cannula is a medical device used to facilitate heated humidified high-flow therapy that is also known as high-flow therapy. The cannula is a part of a respiratory support system that is used for delivering a consistent flow of medical gas to patients suffering from respiratory conditions. The main attribute of the high-flow nasal cannula is that it aids the supply of 60 liters of medical gas per minute as well as 100% oxygen. The high-flow nasal cannula has assisted in replacing the traditionally used medical gas delivery system nasal cannula that is capable of supplying 1-6 liters per minute of medical gas.
Since the equipment supports high flow, the medical needs of patients suffering from life-threatening or serious respiratory conditions can be met. It is typically used for patients who are breathing voluntarily but are facing respiratory obstruction or failure caused by conditions such as bronchiolitis, acute exacerbations of chronic obstructive pulmonary disease (COPD), congestive heart failure, asthma, pneumonia, and some others. The industry for high-flow nasal cannula is growing at a rapid rate owing to the increasing number of patients across the globe. During the forecast period, the demand for high-performance high-flow nasal cannulas is likely to continue growing.
Rising number of patients reporting acute exacerbations of COPD to drive market growth
The global high-flow nasal cannula market is projected to grow owing to the increasing number of patients with acute exacerbations of COPD. The condition is a chronic inflammatory lung disease and leads to obstruction of airflow from the lungs. The main reasons for a patient developing COPD include excessive exposure to particulate matter or irritating gasses such as cigarette smoke. Associated symptoms are mucus, cough, difficulty in breathing, and wheezing. As indicated by studies, people with COPD are at a higher risk of lung cancer, development of more serious heart diseases, and other critical conditions. As per statistics published by the World Health Organization (WHO), more than 3.23 million deaths were reported caused by chronic obstructive pulmonary disorder. It is considered the third-largest leading cause of death across the globe. Acute exacerbations refers to COPD symptoms worsening at a rapid rate leading to extreme difficulty in breathing. Some of the noted triggers for the sudden spike are changes in weather conditions, respiratory infection, or non-compliance to medical treatment. In such cases, the high-flow nasal cannula is used as a primary treatment procedure since it supplies an essential quantity of oxygen until the symptoms are treated.
Rising air pollution globally to push for higher demand
Air pollution is a global issue. It concerns the health of the general population since rising levels of fine particulate matter in the air combined with the release of harmful gasses can trigger exciting respiratory conditions in patients while inducing breathing issues in newborns or people with no previous history of breathing issues. For instance, air pollution leads to a supply of poor-quality air that lacks sufficient oxygen levels leading to serious medical issues in people breathing such air. The global high-flow nasal cannula market size will increase in case air pollution continues to rise.
High cost of equipment and subsequent treatment to restrict market growth
The cost of a high-flow nasal cannula is high. For instance, on average, the price of a typical high-flow nasal cannula starts from USD 2000 and may go upward depending on the functionalities and other attributes. In addition to this, a study published by the National Institute of Health (NIH) reported that the expected cost of use of high-flow nasal cannula per patient in the US was around USD 368. Furthermore, the cost of overall treatment is even higher since it consists of other associated expenses such as hospital stay, insurance coverage, complementary medical treatments, and other miscellaneous costs. The high-flow nasal cannula industry growth is likely to be restricted due to the high cost of equipment and the overall treatment.
Rising launch of new-age high-flow nasal cannula to create further growth possibilities
Since the impact of COVID-19, more investments have been made into developing superior-performance high-flow nasal cannulas that meet patients' needs and medical demands leading to a pleasant rise in the number of advanced options available in the market. For instance, the Intersurgical i-flo™ high flow nasal cannula developed by Intersurgical, a provider of complete respiratory systems, focuses on task delivery and patient comfort. It is an adult single-use patient interface and includes multiple unique features.
Growing global healthcare expenditure to allow more medical centers access to high-flow nasal cannulas
The rising number of patients and increasing demand for equal access to medical care has caused a surge in global healthcare expenditure borne by regional governments and private healthcare companies. With an increase in the number of medical centers being built worldwide, the demand for high-flow nasal cannulas is projected to push the global market growth trend in the coming years.
Effective resource management due to strict guidelines to create growth challenges
The high-flow nasal cannula industry is subject to strict guidelines and regulatory measures that change from one region to another. Since these devices are critical to patient health, there is no scope for error. Managing crucial resources such as time and money while adhering to dynamic compliance rules may pose a challenge for the companies operating in the sector.
The global high-flow nasal cannula market is segmented based on end-user, application, component, and region.
Based on end-user, the global market segments are long-term care centers, hospitals, ambulatory care services, and others. In 2022, the highest growth was registered in the hospital's segment since they are considered as the primary point of initial care for all medical conditions. They are well-equipped to handle severe cases of respiratory disorders. Growing investments in hospitals could create higher segmental growth. As of 2021, Australia had around 697 public hospitals.
Based on application, the high-flow nasal cannula industry divisions are carbon monoxide toxicity, acute respiratory failure, bronchiectasis, chronic obstructive pulmonary disease (COPD), sleep apnea, and others.
Based on component, the global market is segmented into nasal cannulas, air humidifiers, single-heated tubes, air/oxygen blenders, and others. In 2022, the nasal cannulas segment accounted for over 60.1% of the total share driven by the growing number of patients with respiratory conditions. The rising prevalence of asthma and COPD could be key segmental drivers during the projection period.
|Report Attributes||Report Details|
|Report Name||High-flow Nasal Cannula Market|
|Market Size in 2022||USD 7.45 Billion|
|Market Forecast in 2030||USD 18.65 Billion|
|Growth Rate||CAGR of 12.18%|
|Number of Pages||228|
|Key Companies Covered||Teleflex Incorporated, Fisher & Paykel Healthcare, Becton, Dickinson and Company (BD), Vapotherm, Drive DeVilbiss Healthcare, ResMed, Flexicare Medical Limited, Hamilton Medical, Invacare Corporation, Salter Labs, Precision Medical Inc., Besmed Health Business Corp., Smiths Medical, Great Group Medical Co. Ltd., Inogen Inc., and others.|
|Segments Covered||By End-User, By Application, By Component, and By Region|
|Regions Covered||North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)|
|Historical Year||2017 to 2021|
|Forecast Year||2023 - 2030|
|Customization Scope||Avail customized purchase options to meet your exact research needs. Request For Customization|
North America to register higher growth during the assessment timeframe
The global high-flow nasal cannula market is expected to be led by North America by 2030. In 2022, the region generated over 50% of the global sales. Factors such as the presence of a robust medical infrastructure, the existence of key medical device manufacturers and suppliers, and increasing demand for non-invasive medical treatments for respiratory conditions contribute to regional dominance. In February 2021, Masimo, a US-based global medical technology company, announced the US launch of softFlow®. It is a novel pulmonary care therapy using a high-flow nasal cannula. North America was one of the most significantly impacted regions during COVID-19 prompting official authorities to take serious actions toward preventing such incidents in the future. Asia-Pacific is expected to grow at a steady pace. Increasing healthcare expenditure, rising air pollution rate, and growing investments in the development of new medical centers to meet the needs of the surging population could act as main regional growth drivers.
The global high-flow nasal cannula market is led by players like:
A high-flow nasal cannula is a medical device used to facilitate heated humidified high-flow therapy that is also known as high-flow therapy.
The global high-flow nasal cannula market is projected to grow owing to the increasing number of patients with acute exacerbations of COPD.
According to study, the global high-flow nasal cannula market size was worth around USD 7.45 billion in 2022 and is predicted to grow to around USD 18.65 billion by 2030.
The CAGR value of the high-flow nasal cannula market is expected to be around 12.18% during 2023-2030.
The global high-flow nasal cannula market is expected to be led by North America by 2030.
The global high-flow nasal cannula market is led by players like Teleflex Incorporated, Fisher & Paykel Healthcare, Becton, Dickinson and Company (BD), Vapotherm, Drive DeVilbiss Healthcare, ResMed, Flexicare Medical Limited, Hamilton Medical, Invacare Corporation, Salter Labs, Precision Medical, Inc., Besmed Health Business Corp., Smiths Medical, Great Group Medical Co., Ltd., and Inogen, Inc.
The report explores crucial aspects of the high-flow nasal cannula market including a detailed discussion of existing growth factors and restraints while also browsing future growth opportunities and challenges that impact the market.